Trials / Completed
CompletedNCT04412044
Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
22 asthmatics, in which mepolizumab was to be started, gave permission for inclusion and were followed up prospectively. Clinical and lung functional data, sputum analyses and cytokine measurements were analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mepolizumab Injection [Nucala] | Patients receive monthly injection with 100 mg mepolizumab |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-05-01
- Completion
- 2019-03-01
- First posted
- 2020-06-02
- Last updated
- 2020-06-02
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04412044. Inclusion in this directory is not an endorsement.